Common germline polymorphisms associated with breast cancer-specific survival

Breast Cancer Research

Volumn 17, Issue 1, 2015, Pages

  Pirie, Ailith ^a   Guo, Qi ^a   Kraft, Peter ^b   Canisius, Sander ^c   Eccles, Diana M ^d   Rahman, Nazneen ^e   Nevanlinna, Heli ^f   Chen, Constance ^b   Khan, Sofia ^f   Tyrer, Jonathan ^a   Bolla, Manjeet K ^a   Wang, Qin ^a   Dennis, Joe ^a   Michailidou, Kyriaki ^a   Lush, Michael ^a   Dunning, Alison M ^a   Shah, Mitul ^a   Czene, Kamila ^g   Darabi, Hatef ^g   Eriksson, Mikael ^g   Lambrechts, Dieter ^h,i   Weltens, Caroline ^j   Leunen, Karin ^j   van Ongeval, Chantal ^j   Nordestgaard, Børge G ^k,l   Nielsen, Sune F ^k   Flyger, Henrik ^k   Rudolph, Anja ^m   Seibold, Petra ^m   Flesch Janys, Dieter ⁿ   Blomqvist, Carl ^f   Aittomäki, Kristiina ^f   Fagerholm, Rainer ^f   Muranen, Taru A ^f   Olsen, Janet E ^o   Hallberg, Emily ^o   Vachon, Celine ^o   Knight, Julia A ^p,q   Glendon, Gord ^r   Mulligan, Anna Marie ^s,t   Broeks, Annegien ^c   Cornelissen, Sten ^c   Haiman, Christopher A ^u   Henderson, Brian E ^u   Schumacher, Frederick ^u   Le Marchand, Loic ^v   Hopper, John L ^w   Tsimiklis, Helen ^x   Apicella, Carmel ^w   Southey, Melissa C ^x   Cross, Simon S ^y   Reed, Malcolm W R ^y   Giles, Graham G ^w,z   Milne, Roger L ^w,z   McLean, Catriona ^aa   Winqvist, Robert ^ab   Pylkäs, Katri ^ab   Jukkola Vuorinen, Arja ^ab   Grip, Mervi ^ac   Hooning, Maartje J ^ad   Hollestelle, Antoinette ^ad   Martens, John W M ^ad   van den Ouweland, Ans M W ^ad   Marme, Federick ^ae   Schneeweiss, Andreas ^ae   Yang, Rongxi ^ae   Burwinkel, Barbara ^m,ae   Figueroa, Jonine ^af   Chanock, Stephen J ^af,ag   Lissowska, Jolanta ^ah   Sawyer, Elinor J ^ai   Tomlinson, Ian ^aj   Kerin, Michael J ^ak   Miller, Nicola ^ak   Brenner, Hermann ^m   Butterbach, Katja ^m   Holleczek, Bernd ^al   Kataja, Vesa ^am   Kosma, Veli Matti ^am,an   Hartikainen, Jaana M ^am,an   Li, Jingmei ^g   Brand, Judith S ^g   Humphreys, Keith ^g   Devilee, Peter ^ao   Tollenaar, Robert A E M ^ao   Seynaeve, Caroline ^ad   Radice, Paolo ^ap   Peterlongo, Paolo ^aq   Manoukian, Siranoush ^ap   Ficarazzi, Filomena ^aq,ar   Beckmann, Matthias W ^as   Hein, Alexander ^as   Ekici, Arif B ^as   Balleine, Rosemary ^at   Phillips, Kelly Anne ^w,au,av   Benitez, Javier ^aw,ax   Zamora, M Pilar ^ay   Perez, Jose Ignacio Arias ^az   Menéndez, Primitiva ^az   Jakubowska, Anna ^ba   Lubinski, Jan ^ba   Gronwald, Jacek ^ba   Durda, Katarzyna ^ba   Hamann, Ute ^m   Kabisch, Maria ^m   Ulmer, Hans Ulrich ^bb   Rüdiger, Thomas ^bc   Margolin, Sara ^g   Kristensen, Vessela ^bd,be   Nord, Siljie ^bd,be   Evans, D Gareth ^bf   Abraham, Jean ^a,bg,bh   Earl, Helena ^bg,bh   Poole, Christopher J ^bi   Hiller, Louise ^bi   Dunn, Janet A ^bi   Bowden, Sarah ^bj   Yang, Rose ^af   Campa, Daniele ^m,bk   Diver, W Ryan ^bl   Gapstur, Susan M ^bl   Gaudet, Mia M ^bl   Hankinson, Susan ^b,bm,bn   Hoover, Robert N ^af   Hüsing, Anika ^m   Kaaks, Rudolf ^m   Machiela, Mitchell J ^af   Willett, Walter ^b   Barrdahl, Myrto ^m   Canzian, Federico ^m   Chin, Suet Feung ^a   Caldas, Carlos ^a,bg,bh   Hunter, David J ^b   Lindstrom, Sara ^b   Garcia Closas, Montserrat ^e   Couch, Fergus J ^o   Chenevix Trench, Georgia ^bo   Mannermaa, Arto ^am,an   Andrulis, Irene L ^r,s   Hall, Per ^g   Chang Claude, Jenny ^m   Easton, Douglas F ^a   Bojesen, Stig E ^k,l   Cox, Angela ^y   Fasching, Peter A ^as,bp   Pharoah, Paul D P ^a   Schmidt, Marjanka K ^c   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Antoni Van Leeuwenhoek Hospital Netherlands Cancer Institute   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g KAROLINSKA INSTITUTE   (Sweden)

^h Vesalius Research Center (VRC)   (Belgium)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k Mental Health Center Glostrup   (Denmark)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^o MAYO CLINIC   (United States)

^p MOUNT SINAI HOSPITAL   (Canada)

^q UNIVERSITY OF TORONTO   (Canada)

^r CANCER CARE ONTARIO   (Canada)

^s UNIVERSITY OF TORONTO   (Canada)

^t UNIVERSITY HEALTH NETWORK   (Canada)

^u UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^v UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^w UNIVERSITY OF MELBOURNE   (Australia)

^x UNIVERSITY OF MELBOURNE   (Australia)

^y UNIVERSITY OF SHEFFIELD   (United Kingdom)

^z CANCER EPIDEMIOLOGY CENTRE   (Australia)

^aa ALFRED HOSPITAL   (Australia)

^ab UNIVERSITY OF OULU   (Finland)

^ac OULU UNIVERSITY HOSPITAL   (Finland)

^ad ERASMUS MC CANCER INSTITUTE   (Netherlands)

^ae UNIVERSITY OF HEIDELBERG   (Germany)

^af NATIONAL CANCER INSTITUTE   (United States)

^ag FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^ah INSTITUTE OF ONCOLOGY   (Poland)

^ai BHF Centre for Regenerative Medicine and BHF Centre of Excellence and the Biomedical Research Centre at Guy s St Thomas NHS Foundation Trust and King s College London   (United Kingdom)

^aj UNIVERSITY OF OXFORD   (United Kingdom)

^ak UNIVERSITY HOSPITAL GALWAY   (Ireland)

^al SAARLAND CANCER REGISTRY   (Germany)

^am KUOPIO UNIVERSITY HOSPITAL   (Finland)

^an UNIVERSITY OF EASTERN FINLAND   (Finland)

^ao LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^ap NATIONAL CANCER INSTITUTE   (Italy)

^aq FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^ar M Sklodowska Curie Memorial Cancer Center and Institute of Oncology Department of Cancer Epidemiology and Prevention ^*  (Italy)

^as UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^at WESTMEAD HOSPITAL   (Australia)

^au PETER MACCALLUM CANCER CENTRE   (Australia)

^av UNIVERSITY OF MELBOURNE   (Australia)

^aw Structural Biology and Biocomputing Programme   (Spain)

^ax CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^ay HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^az HOSPITAL MONTE NARANCO   (Spain)

^ba POMERANIAN MEDICAL UNIVERSITY   (Poland)

^bb Frauenklinik der Stadtklinik Baden Baden   (Germany)

^bc STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^bd UNIVERSITY OF OSLO   (Norway)

^be OSLO UNIVERSITY HOSPITAL   (Norway)

^bf UNIVERSITY OF MANCHESTER   (United Kingdom)

^bg Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^bh CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^bi UNIVERSITY OF WARWICK   (United Kingdom)

^bj UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^bk UNIVERSITY OF PISA   (Italy)

^bl AMERICAN CANCER SOCIETY   (United States)

^bm UNIVERSITY OF MASSACHUSETTS   (United States)

^bn BRIGHAM AND WOMEN S HOSPITAL   (United States)

^bo QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^bp UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; GERM LINE; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; BREAST TUMOR; FEMALE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GERM CELL; META ANALYSIS; METABOLISM; MORTALITY; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GERM CELLS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84933050272     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-015-0570-7     Document Type: Article

References (67)

1. IARC. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx .
2. Hartman M, Lindström L, Dickman PW, Adami H-O, Hall P, Czene K. Is breast cancer prognosis inherited? Breast Cancer Res. 2007;9:R39.
3. Ribelles N, Santonja A, Pajares B, Llácer C, Alba E. The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. Cancer Treat Rev. 2014;40:293-9.
4. Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, et al. Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst. 2010;102:650-62.
5. Azzato EM, Pharoah PDP, Harrington P, Easton DF, Greenberg D, Caporaso NE, et al. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:1140-3.
6. Shu XO, Long J, Lu W, Li C, Chen WY, Delahanty R, et al. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res. 2012;72:1182-9.
7. Fasching P, Pharoah PDP, Cox A, Nevanlinna H, Bojesen SE, Karn T, et al. The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet. 2012;21:3926-39.
8. Guo Q, Schmidt MK, Kraft P, Canisius S, Chen C, Khan S, et al. JNCI J Natl Cancer Inst 2015;107(5):djv081 doi:10.1093/jnci/djv081.
9. Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Res. 2014;20:2466-75.
10. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-52.
11. Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2 × 2 factorial randomised phase 3 trial. Lancet Oncol. 2014;15:201-12.
12. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG. Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer. 2007;7:160.
13. Einarsdóttir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, et al. ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res. 2008;10:R15.
14. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40:844-53.
15. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870-4.
16. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45:353-61.
17. Poole CJ, Hiller L, Howard HC, Dunn JA, Canney P, Wardley AM, et al. tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). ASCO Meet Abstr. 2008;26:506.
18. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355:1851-62.
19. Siddiq A, Couch FJ, Chen GK, Lindström S, Eccles D, Millikan RC, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012;21:5373-84.
20. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491:56-65.
21. Bryant EK, Dressen AS, Bunker CH, Hokanson JE, Hamman RF, Kamboh MI, et al. A multiethnic replication study of plasma lipoprotein levels-associated SNPs identified in recent GWAS. PLoS One. 2013;8, e63469.
22. Long JR, Cai Q, Shu XO, Cai H, Gao YT, Zheng W. Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival. Pharmacogenet Genomics. 2007;17:331-8.
23. Slattery ML, John E, Torres-Mejia G, Stern M, Lundgreen A, Hines L, et al. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One. 2013;8, e63165.
24. You Y, Deng J, Zheng J, Hu M, Li N, Wu H, et al. IL-21 gene polymorphism is associated with the prognosis of breast cancer in Chinese populations. Breast Cancer Res Treat. 2013;137:893-901.
25. Hindorff LA, MacArthur J, Morales J, Junkins HA, Hall PN, Klemm AK et al: A catalog of published genome-wide association studies. Available at: www.genome.gov/gwastudies . Accessed 22 Aug 2013.
26. Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358:2796-803.
27. Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12:R1.
28. Bewick MA, Conlon MSC, Lafrenie RM. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol. 2006;24:5645-51.
29. Bewick MA, Lafrenie RM, Conlon MSC. Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer. J Cancer Res Clin Oncol. 2011;137:543-50.
30. Castro E, Olmos D, Garcia A, Cruz JJ, González-Sarmiento R. Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients. Clin Transl Oncol. 2014;16:158-65.
31. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BAJ, et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res. 2002;62:3052-7.
32. Lin WY, Camp NJ, Cannon-Albright LA, Allen-Brady K, Balasubramanian S, Reed MWR, et al. A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet. 2011;48:477-84.
33. Azzato EM, Driver KE, Lesueur F, Shah M, Greenberg D, Easton DF, et al. Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res. 2008;10:R47.
34. Bayraktar S, Thompson PA, Yoo SY, Do K, Sahin AA, Arun BK, et al. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013;18:493-500.
35. Jamshidi M, Schmidt MK, Dörk T, Garcia-Closas M, Heikkinen T, Cornelissen S, et al. Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. Int J Cancer. 2013;132:2044-55.
36. Pei R, Xu Y, Wei Y, Ouyang T, Li J, Wang T, et al. Association of SIPA1 545 C > T polymorphism with survival in Chinese women with metastatic breast cancer. Front Med. 2013;7:138-42.
37. Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van't Veer LJ, Pharoah PDP, et al. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res. 2009;11:R89.
38. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res. 2005;11:5098-103.
39. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 2007;9:R34.
40. Beeghly-Fadiel A, Shu XO, Long J, Li C, Cai Q, Cai H, et al. Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int J Cancer. 2009;124:208-14.
41. Beeghly-Fadiel A, Zheng W, Lu W, Long J, Zheng Y, Cai H, et al. Replication study for reported SNP associations with breast cancer survival. J Cancer Res Clin Oncol. 2012;138:1019-26.
42. Decock J, Long J-R, Laxton RC, Shu X-O, Hodgkinson C, Hendrickx W, et al. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 2007;67:10214-21.
43. Peterson NB, Beeghly-Fadiel A, Gao YT, Long J, Cai Q, Shu X, et al. Polymorphisms in tissue inhibitors of metalloproteinases -2 and -3 and breast cancer susceptibility and survival. Int J Cancer. 2010;125:844-50.
44. Ambrosone CB, Ahn J, Singh KK, Furberg H, Sweeney C, Coles B, et al: 804 Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and 805 survival after treatment for breast cancer. Cancer Res. 2005: 1105-11.
45. Ambrosone CB, Ahn J, Singh KK, Furberg H, Sweeney C, Coles B, et al: Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. 2005: 1105-11.
46. Buck K, Hug S, Seibold P, Ferschke I, Altevogt P, Sohn C, et al. CD24 polymorphisms in breast cancer: impact on prognosis and risk. Breast Cancer Res Treat. 2013;137:927-37.
47. Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, Chung HW, et al. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1090-5.
48. Demichele A, Martin A, Mick R, Gor P, Wray L, Klein-Cabral M, et al. Interleukin-6 174G3 C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 2003: 8051-56.
49. Duggan C, Ballard-Barbash R, Baumgartner RN, Baumgartner KB, Bernstein L, McTiernan A. Associations between null mutations in GSTT1 and GSTM1, the GSTP1 Ile(105)Val polymorphism, and mortality in breast cancer survivors. Springerplus. 2013;2:450.
50. Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat. 2008;112:89-98.
51. Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, et al. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat. 2010;119:701-5.
52. Hartikainen JM, Tengström M, Kosma VM, Kinnula VL, Mannermaa A, Soini Y. Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer. Cancer Res. 2012;72:5537-46.
53. Jiang L, Deng J, Zhu X, Zheng J, You Y, Li N, et al. CD44 rs13347 C > T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res. 2012;14:R105.
54. Lee JH, Kim Y, Choi JW, Kim YS. Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis. Arch Med Res. 2013;44:39-45.
55. Long JR, Kataoka N, Shu XO, Wen W, Gao YT, Cai Q, et al. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev. 2006;15:2115-22.
56. Sweeney C, Mcclure GY, Fares MY, Stone A, Coles BF, Thompson PA, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism advances in brief association between survival after treatment for breast cancer and glutathione. Cancer Res. 2000: 5621-24.
57. Yang CX, Li CY, Feng W. Toll-like receptor 4 genetic variants and prognosis of breast cancer. Tissue Antigens. 2013;81:221-6.
58. Choi JY, Lee KM, Noh DY, Ahn SH, Lee JE, Han W, et al. Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat. 2006;100:213-8.
59. Kontogianni P, Zambirinis CP, Theodoropoulos G, Gazouli M, Michalopoulos NV, Flessas J, et al. The impact of the stromal cell-derived factor-1-3'A and E-selectin S128R polymorphisms on breast cancer. Mol Biol Rep. 2013;40:43-50.
60. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 2005;65:5015-9.
61. Otterbach F, Callies R, Frey UH, Schmitz KJ, Wreczycki C, Kimmig R, et al. The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma. Breast Cancer Res Treat. 2007;105:311-7.
62. Qu S, Long J, Cai Q, Shu XO, Cai H, Gao YT, et al. Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival. Clin Cancer Res. 2008;14:4787-93.
63. Shu XO. Genetic polymorphisms in the TGF-1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res. 2004;64:836-9.
64. Upadhyay R, Sanduja S, Kaza V, Dixon DA. Genetic polymorphisms in RNA binding proteins contribute to breast cancer survival. Int J Cancer. 2013;132:E128-38.
65. Pande M, Thompson PA, Do KA, Sahin AA, Amos CI, Frazier ML, et al. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis. 2013;34:587-94.
66. Perna L, Butterbach K, Haug U, Schöttker B, Müller H, Arndt V, et al. Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev. 2013;22:437-42.
67. Martin DN, Boersma BJ, Howe TM, Goodman JE, Mechanic LE, Chanock SJ, et al. Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer. 2006;6:257.